Immuron, Ltd.

Sponsored ADR (1 ADS : 20 Ordinary) International Reporting
Verified Company Profile 9/06/2016
Contact Info
  • Suite 1
  • 1233 High Street
  • Armadale, VIC 3143
  • Australia

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: ASX - Australian Securities Exchange
Audited Financials Audited
Latest Report Jun 30, 2016 Annual Report
CIK 0001416282
Fiscal Year End 6/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: Australia
Year of Inc. 1994
Employees 12 a/o Sep 02, 2015
Company Officers/Contacts
Dr.Jerry Kanellos COO, Chief Scientific Officer
Peter Vaughan CFO, Secretary
Phillip Allen Hains CFO, Secretary
Dr. Dan Peres Senior VP, SVP, Product Dev.
Company Directors
Agapitos Elefterios 'Peter' Anastasiou Executive Vice Chairman
Dr. Roger Aston Non-Executive Chairman
Daniel Jude Pollock Non-Executive Director
Stephen Anastasiou Non-Executive Director
Company Notes
  • Formerly=Anadis Ltd. until 12-2008
Service Providers
Accounting/Auditing Firm
Not Available
Legal Counsel
Sichenzia Ross Friedman Ference LLP
61 Broadway
32nd Floor
New York, NY, 10006
United States

Investor Relations Firm
Not Available
IMROY Security Details
Share Structure
Market Value1 Not Available
Authorized Shares Unlimited a/o Sep 03, 2016
Outstanding Shares 101,420,624 a/o Sep 04, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value No Par Value
Transfer Agent(s)
BNY Mellon
Shareholders of Record 1,334 a/o Sep 04, 2016
Non US Stock Exchange Listing
IMC - ASX - Australian Securities Exchange - Qualified
Short Selling Data
Short Interest (%)
Significant Failures to Deliver No

1Market Value calculated only for respective security